239

45 - settembre 2019 - Minuti daches in the United States: a review of statistics from na- tional surveillance studies. Headache. 2013; 53(3):4 27-436. 2. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF; AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neuro- logy. 2007;6 8(5):3 43-349. 3. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2013;3 3(9):6 29-808. 4. Katsarava Z, Buse DC, Manack AN, Lipton RB. Defi- ning the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012;1 6(1):8 6-92. 5. Starling AJ, Dodick DW. Best practices for patients with chronic migraine: burden, diagnosis, and management in pri- mary care. Mayo Clin Proc. 2015;9 0(3):4 08-414. 6. Kelman L. The triggers or precipitants of the acute mi- graine attack. Cephalalgia. 2007;2 7(5):3 94-402. 7. Modi S, Lowder DM. Medications for migraine pro- phylaxis [published correction appears in Am Fam Physician. 2006;7 4(10):1 685]. Am Fam Physician. 2006;7 3(1):7 2- 78. 8. Silberstein SD. Preventive migraine treatment. Conti- nuum (Minneap Minn). 2015;2 1(4 Headache):9 73-989. 9. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmaco- logic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the Ame- rican Academy of Neurology and the American Headache So- ciety [published correction appears in Neurology. 2013; 80(9):8 71]. Neurology. 2012;7 8(17):1 337-1345. 10. Loder E, Burch R, Rizolli P. The 2012 AHS/AAN gui- delines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache. 2012;5 2(6):9 30-945. 11. Silberstein SD. Practice parameter: evidence-based gui- delines for migraine headache (an evidence-based review): re- port of the Quality Standards Subcommittee of the American Academy of Neurology [published correction appears in Neu- rology. 2000;5 6(1):1 42]. Neurology. 2000;5 5(6):7 54-762. 12. Linde K, Rossnagel K. Propranolol for migraine pro- phylaxis. Cochrane Database Syst Rev. 2004;( 2):C D003225. 13. Jackson JL, Cogbill E, Santana-Davila R, et al. A com- parative effectiveness meta-analysis of drugs for the prophy- laxis of migraine headache. PLoS One. 2015;1 0(7):e 0130733. 14. Schellenberg R, Lichtenthal A, Wöhling H, Graf C, Bri- xius K. Nebivolol and metoprolol for treating migraine: an advance on beta-blocker treatment? Headache. 2008;4 8(1):1 18-125. 15. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Valproate (valproic acid or sodium valproate or a combina- tion of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013; (6):C D010611. 16. Freitag FG, Collins SD, Carlson HA, et al.; Depakote ER Migraine Study Group. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neu- rology. 2002;5 8(11):1 652-1659. 17. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;( 6):C D010610. 18. Dodick DW, Freitag F, Banks J, et al.; CAPSS-277 In- vestigator Group. Topiramate versus amitriptyline in mi- graine prevention: a 26-week, multicenter, randomized, dou- ble-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther. 2009;3 1(3):5 42-559. 19. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Gabapentin or pregabalin for the prophylaxis of episodic mi- graine in adults. Cochrane Database Syst Rev. 2013;( 6):C D010609. 20. Xu XM, Liu Y, Dong MX, Zou DZ, Wei YD. Tricyclic antidepressants for preventing migraine in adults. Medicine (Baltimore). 2017;9 6(22):e 6989. 21. Bulut S, Berilgen MS, Baran A, Tekatas A, Atmaca M, Mungen B. Venlafaxine versus amitriptyline in the prophy- lactic treatment of migraine: randomized, double-blind, cros- sover study. Clin Neurol Neurosurg. 2004; 107(1):4 4-48. 22. Adly C, Straumanis J, Chesson A. Fluoxetine prophyla- xis of migraine. Headache. 1992;3 2(2):1 01-104. 23. Saper JR, Silberstein SD, Lake AE III, Winters ME. Dou- ble-blind trial of fluoxetine: chronic daily headache and mi- graine. Headache. 1994;3 4(9): 497-502. 24. Schrader H, Stovner LJ, Helde G, Sand T, BovimG. Pro- phylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo control- led, crossover study. BMJ. 2001; 322(7277):1 9-22. 25. Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Pro- phylactic treatment of migraine with an angiotensin II re- ceptor blocker: a randomized controlled trial. JAMA. 2003;2 89(1):6 5-69. 26. Diener HC, Gendolla A, Feuersenger A, et al. Telmi- sartan in migraine prophylaxis: a randomized, placebo-con- trolled trial. Cephalalgia. 2009; 29(9):9 21-927. 27. Simpson DM, Hallett M, Ashman EJ, et al. Practice gui- deline update summary: Botulinum neurotoxin for the tre- atment of blepharospasm, cervical dystonia, adult spasti- city, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neu- rology. 2016;8 6(19):1 818-1826. 28. Goadsby PJ, Reuter U, Hallström Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;3 77(22):2 123-2132. 29. Rajapakse T, Pringsheim T. Nutraceuticals in migraine: a summary of existing guidelines for use. Headache. 2016;5 6(4):8 08-816. 30. Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E; Quality Standards Subcommittee of the American Academy of Neurology and the American Heada- che Society. Evidence-based guideline update: NSAIDs and